Literature DB >> 27560775

Fentanyl Law Enforcement Submissions and Increases in Synthetic Opioid-Involved Overdose Deaths - 27 States, 2013-2014.

R Matthew Gladden1, Pedro Martinez, Puja Seth.   

Abstract

In March and October 2015, the Drug Enforcement Administration (DEA) and CDC, respectively, issued nationwide alerts identifying illicitly manufactured fentanyl (IMF) as a threat to public health and safety (1,2). IMF is unlawfully produced fentanyl, obtained through illicit drug markets, includes fentanyl analogs, and is commonly mixed with or sold as heroin (1,3,4). Starting in 2013, the production and distribution of IMF increased to unprecedented levels, fueled by increases in the global supply, processing, and distribution of fentanyl and fentanyl-precursor chemicals by criminal organizations (3). Fentanyl is a synthetic opioid 50-100 times more potent than morphine (2).* Multiple states have reported increases in fentanyl-involved overdose (poisoning) deaths (fentanyl deaths) (2). This report examined the number of drug products obtained by law enforcement that tested positive for fentanyl (fentanyl submissions) and synthetic opioid-involved deaths other than methadone (synthetic opioid deaths), which include fentanyl deaths and deaths involving other synthetic opioids (e.g., tramadol). Fentanyl deaths are not reported separately in national data. Analyses also were conducted on data from 27 states(†) with consistent death certificate reporting of the drugs involved in overdoses. Nationally, the number of fentanyl submissions and synthetic opioid deaths increased by 426% and 79%, respectively, during 2013-2014; among the 27 analyzed states, fentanyl submission increases were strongly correlated with increases in synthetic opioid deaths. Changes in fentanyl submissions and synthetic opioid deaths were not correlated with changes in fentanyl prescribing rates, and increases in fentanyl submissions and synthetic opioid deaths were primarily concentrated in eight states (high-burden states). Reports from six of the eight high-burden states indicated that fentanyl-involved overdose deaths were primarily driving increases in synthetic opioid deaths. Increases in synthetic opioid deaths among high-burden states disproportionately involved persons aged 15-44 years and males, a pattern consistent with previously documented IMF-involved deaths (5). These findings, combined with the approximate doubling in fentanyl submissions during 2014-2015 (from 5,343 to 13,882) (6), underscore the urgent need for a collaborative public health and law enforcement response.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27560775     DOI: 10.15585/mmwr.mm6533a2

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  127 in total

1.  Illicit fentanyls in the opioid street market: desired or imposed?

Authors:  Sarah G Mars; Daniel Rosenblum; Daniel Ciccarone
Journal:  Addiction       Date:  2018-12-04       Impact factor: 6.526

2.  Increases from 2002 to 2015 in prescription opioid overdose deaths in combination with other substances.

Authors:  Denise B Kandel; Mei-Chen Hu; Pamela Griesler; Melanie Wall
Journal:  Drug Alcohol Depend       Date:  2017-07-04       Impact factor: 4.492

3.  Density of low-barrier opioid agonist clinics and risk of non-fatal overdose during a community-wide overdose crisis: A spatial analysis.

Authors:  Ofer Amram; Eugenia Socías; Ekaterina Nosova; Thomas Kerr; Evan Wood; Kora DeBeck; Kanna Hayashi; Nadia Fairbairn; Julio Montaner; M J Milloy
Journal:  Spat Spatiotemporal Epidemiol       Date:  2019-07-04

4.  Who receives naloxone from emergency medical services? Characteristics of calls and recent trends.

Authors:  Caroline Geiger; Rosanna Smart; Bradley D Stein
Journal:  Subst Abus       Date:  2019-07-30       Impact factor: 3.716

5.  Sold as Heroin: Perceptions and Use of an Evolving Drug in Baltimore, MD.

Authors:  Sarah G Mars; Jeff Ondocsin; Daniel Ciccarone
Journal:  J Psychoactive Drugs       Date:  2017-12-06

6.  Assessing Spatial Relationships between Prescription Drugs, Race, and Overdose in New York State from 2013 to 2015.

Authors:  Phillip L Marotta; Tim Hunt; Louisa Gilbert; Elwin Wu; Dawn Goddard-Eckrich; Nabila El-Bassel
Journal:  J Psychoactive Drugs       Date:  2019-05-05

7.  Molecular dynamics of fentanyl bound to μ-opioid receptor.

Authors:  Piotr F J Lipiński; Małgorzata Jarończyk; Jan Cz Dobrowolski; Joanna Sadlej
Journal:  J Mol Model       Date:  2019-05-03       Impact factor: 1.810

8.  A statewide effort to reduce high-dose opioid prescribing through coordinated care organizations.

Authors:  Daniel M Hartung; Lindsey Alley; Gillian Leichtling; P Todd Korthuis; Christi Hildebran
Journal:  Addict Behav       Date:  2018-05-01       Impact factor: 3.913

9.  Addressing Intersecting Housing and Overdose Crises in Vancouver, Canada: Opportunities and Challenges from a Tenant-Led Overdose Response Intervention in Single Room Occupancy Hotels.

Authors:  Geoff Bardwell; Taylor Fleming; Alexandra B Collins; Jade Boyd; Ryan McNeil
Journal:  J Urban Health       Date:  2019-02       Impact factor: 3.671

10.  Perceptions about fentanyl-adulterated heroin and overdose risk reduction behaviors among persons seeking treatment for heroin use.

Authors:  Michael D Stein; Shannon R Kenney; Bradley J Anderson; Genie L Bailey
Journal:  J Subst Abuse Treat       Date:  2019-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.